NCT Number: NCT06736145
The aim of this work is to record changes on accessory muscles especially sternocleidomastoid and scalene after applying cervical NAGs in COPD patients.
Interested in participating?
Request Info20 year–50 year
All sexes
Interventional
Not applicable
Islamabad, Federal, 04485, Pakistan
Location status: Recruiting
Asmar Fatima, MS-OMPT
SUB_INVESTIGATOR
Asmar Fatima, MSOMPT
CONTACT
Ghaniya Khan, MSOMPT*
PRINCIPAL_INVESTIGATOR
Ghaniya Khan, MS_OMPT*
CONTACT
Natural gliding movements in the spine, known as apophyseal glides, occur during breathing. These movements are believed to be important for maintaining good posture and flexibility in the spine. In COPD patients, the muscles that support the spine, like the scalene and SCM, can become tight and strained due to labored breathing. This tightness can lead to neck and shoulder pain.
While studies suggest that natural apophyseal glides improve spinal mobility, accessory muscle flexibility and reduce pain, there is room for further research on COPD patients, especially in Pakistan.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week
Total of 9 sessions were given each consisting of 40 mins.
Natural Apophyseal Glides of Cervical spine are given 3 repetitions x 3-6 sets, 3 days/week.
Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week
Total of 9 sessions were given each consisting of 40 mins.
Time frame: 3rd week
Changes from baseline ROM range of motion for cervical flexion,etension, lateral flexion and rotation is measured using tape
Time frame: 3rd week
Changes from baseline for pain is measured using NPRS. NPRS stands for Numerical Pain Rating Scale, a common method for assessing pain intensity. It's a simple scale from 0 to 10, where: 0 represents no pain, 1-3 represents mild pain, 4-6 represents moderate pain, 7-10 represents severe pain. Patients are asked to rate their pain by choosing a number on this scale to evaluate and monitor pain levels before and after treatment.
Time frame: 3rd week
Changes for baseline for level of Shortness of breath is measured using Dyspnea Index. The dyspnea index, also known as the Modified Medical Research Council (MMRC) scale, measures the severity of breathlessness or dyspnea. It's a 5-point scale: Grade 0: No dyspnea, Grade 1: Dyspnea during strenuous exercise, Grade 2: Dyspnea during moderate exercise, Grade 3: Dyspnea during light exercise or walking on level ground, Grade 4: Dyspnea during daily activities or at rest. This scale helps assess the impact of treatment on copd patients.
Time frame: 3rd week
Changes from baseline for level of kinesiophobia is measured using Tampa scale. The most widely used scale for assessing kinesiophobia is the Tampa Scale of Kinesiophobia (TSK). This questionnaire contains 17 items that gauge a person's fear of movement and associated with movement. Each item is rated on a 4-point Likert scale, with a higher score indicating a greater degree of kinesiophobia. It has an excellent reliability of Cronbach Alpha > 0.9 (18).
Scores for each item are added together to get a total score. Scores can range from 17 (low kinesiophobia) to 68 (high kinesiophobia). A cut-off score of 37 is often used to indicate high kinesiophobia in COPD patients.
Contact information is provided by the study sponsor or research team.
Riphah International University
Other
Effects of Cervical Nags on Accessory Muscles in Patients With Copd
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07404826
COPD, Chronic Disease
Cincinnati, Ohio, United States
View Trial DetailsNCT06935825
COPD, Chronic Disease
Amsterdam, Netherlands
View Trial DetailsNCT07566195
COPD, Chronic Disease
Aix-en-Provence, France
View Trial DetailsNCT07567872
COPD, Chronic Disease
Chengdu, Sichuan, China
View Trial Details